Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Pandoraon Apr 04, 2023 5:52pm
476 Views
Post# 35379779

Patent Action Today

Patent Action TodayThe below listed patent application was rejected by the USPTO on January 4, 2023.
The USPTO has now posted the Company's response to that non-final rejection.
Claim 1 is amended, Claims 18 - 22 are cancelled and Claims 23 - 27 are now added.
A lot of the rejection is tied to "failing to comply with the written description requirement".
The cancelled claims (18 - 22) are for an improper grouping of alternatives.
The claims have to do with the methods of using TLD1433 & TLD1824.
The modifications appear moderate but even so the USPTO now has up to 90 days
to say whether they accept them or not.

17/192,569 | T1081/20043:

SONODYNAMIC THERAPY USING SONODYNAMICALLY ACTIVATED COORDINATION COMPLEXES OF TRANSITION METALS AS SENSITIZING AGENTS

Public view
Application #

17/192,569

Confirmation #

5826

Attorney Docket #

T1081/20043

Patent #

-

Filing or 371 (c) date

03/04/2021

Status

Non Final Action Mailed 12/30/2022

Application data

Application type

Utility

Examiner

SAGAR S PATEL

 
Group art unit

1626

Class/subclass

514/492.000

AIA (first inventor to file)

Yes

Entity status

Small

Earliest publication #

US 2022-0296709 A1open_in_new

Earliest publication date

09/22/2022

Assignee for publication
-
Confirmation #
5826
Intl. registration # (Hague)

-

Intl. registration publication date

-

Correspondence address
3000 - CAESAR RIVISE, PC
 
7 Penn Center, 12th Floor
1635 Market Street
PhiladelphiaPA
UNITED STATES
Inventors
  • Arkady Mandel
    North York (CA)
  • Roger Dumoulin-White
    Toronto (CA)
  •  
Applicants
Theralase Technologies, Inc.
Toronto (CA)

Documents & transaction history

 
 
Showing 1 to 22 of 22 entries
 
 
<< Previous
Bullboard Posts
Next >>